HOXD10 expression as a prognostic factor for hepatocellular carcinoma treated with curative resection.
J BUON
; 26(5): 1942-1949, 2021.
Article
in En
| MEDLINE
| ID: mdl-34761603
ABSTRACT
PURPOSE:
HOXD10 downregulation resulting from epigenetic changesas well as its role as a tumor suppressor have been reported in several cancers including hepatocellular carcinomas (HCCs). However, the prognostic role of HOXD10 expression in HCC tissue samples has not been evaluated.METHODS:
HOXD10 expression was investigated in 278 curatively resected HCC samples using immunohistochemistry and its effectiveness in predicting patient outcome was analyzed.RESULTS:
Low expression of HOXD10 was observed in 82.7% of HCC samples, and this was associated with increased age, large tumor size and advanced stage.HOXD10 was an independent predictive factor for early tumor recurrence at less than 2 years. Patients with low HOXD10 expression showed shorter recurrence-free survival (RFS) (p=0.024) and disease-specific survival (DSS) (p=0.016) than those with high expression. Multivariate analysis confirmed that low HOXD10 expression was an independent predictor of shorter RFS (hazard ratio 1.873, p=0.006) and DSS (hazard ratio2.504, p=0.012) than high HOXD10 expression.CONCLUSIONS:
The present study provides clinical evidence supporting the use of HOXD10 as a prognostic biomarker in curatively resected HCCs, and suggests that HOXD10 could also be a potential therapeutic target in HCC.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Transcription Factors
/
Carcinoma, Hepatocellular
/
Homeodomain Proteins
/
Liver Neoplasms
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J BUON
Journal subject:
NEOPLASIAS
Year:
2021
Document type:
Article